If repaglinide monotherapy does not result in adequate glycemic control, metformin or a thiazolidinedione may be added. If metformin or thiazolidinedione monotherapy does not provide adequate control, repaglinide may be added. The starting dose and dose adjustments for repaglinide combination therapy is the same as for repaglinide monotherapy. The dose of each drug should be carefully adjusted to determine the minimal dose required to achieve the desired pharmacologic effect. Failure to do so could result in an increase in the incidence of hypoglycemic episodes. Appropriate monitoring of FPG and HbA1c measurements should be used to ensure that the patient is not subjected to excessive drug exposure or increased probability of secondary drug failure.
Repaglinide Tablets, USP
The 2 mg tablets are light green, round, unscored tablets debossed with M on one side of the tablet and R23 on the other side. They are available as follows:
bottles of 100 tablets
bottles of 500 tablets
NDC 69189-3123-1 single dose pack with 1 tablet as repackaged by Avera McKennan Hospital
Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]
Protect from moisture.
Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.
REVISED SEPTEMBER 2014
| REPAGLINIDE |
|Labeler — Avera McKennan Hospital (068647668)|
|Avera McKennan Hospital||068647668||relabel (69189-3123), repack (69189-3123)|
Revised: 03/2017 Avera McKennan Hospital
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.